Filing Flows › Puma Biotechnology (PBYI) › Q1 2026
Puma Biotechnology (PBYI) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Puma Biotechnology (PBYI) reported revenue of $44.8M for the first quarter 2026 (Q1 2026), -3% from a year earlier and -41% from the quarter before. Operating margin was -8.5%, net loss $3.8M (8.4% of revenue).
Puma Biotechnology, Q1 2026: revenue $44.8M (-3% year over year), operating margin -8.5%, net loss $3.8M, operating cash flow $15.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $44.8M | -41% | -3% |
| Operating profit | −$3.8M | -122% | -196% |
| Net earnings | −$3.8M | -128% | -226% |
| Operating cash flow | $15.4M | +7% | +327% |
What changed
Revenue was $44.8M in Q1 2026, down 3% year over year and down 41% from the previous quarter. Product was the largest line at 94% of revenue. Product lost $1.1M year over year (down 3%), 96% of the total change.
Operating costs exceeded revenue by $3.8M, an operating margin of -8.5%. Total costs grew 16% against a revenue fall of 3%. The fastest-growing cost line was Research & development (+43%). The quarter ended with a net loss of $3.8M, after a profit of $13.4M the previous quarter.
Operating cash flow was $15.4M (up 327% year over year). Non-cash charges added back $2.6M of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items added $14.7M.
Questions
What was Puma Biotechnology's revenue in the first quarter 2026?
Puma Biotechnology (PBYI) reported revenue of $44.8M for the first quarter 2026 (Q1 2026), -3% from a year earlier and -41% from the quarter before.
Was Puma Biotechnology profitable in the first quarter 2026?
Operating loss was $3.8M (-8.5% of revenue) and net loss $3.8M.
Source: Puma Biotechnology 10-Q on SEC EDGAR.